Lifeline BioTechnologies, Inc.’ (LLBO) Affiliate, Cyrcadia, Registers Clinical Trial

RENO, NV--(Marketwired - August 11, 2015) - Lifeline Biotechnologies (OTC PINK: LLBO) announces its affiliate, Cyrcadia, has listed its clinical trial on ClinicalTrials.gov for its wearable breast cancer early detection device at El Camino Hospital, Mountain View, California and upcoming additional clinical study sites. ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database currently holding registrations from over 130,000 trials and more than 170 countries around the world.

For those interested in learning more about the Cyrcadia clinical studies, ClinicalTrials.gov is the registry to use, including all details about the study and its status. It is the only location where Cyrcadia will provide information about the studies and will update the registry from time to time. All information desired about the clinical studies can be obtained there and will not otherwise be provided by Cyrcadia, its staff or other related parties. All details about the study, including descriptions, eligibility and contacts, can be obtained there. Please follow this link: ClinicalTrials.gov/Cyrcadia or go to the ClinicalTrials.gov website using the identifier NCT02511301 to learn more and follow progress of the study as it is reported.

Utilizing Lifeline’s previous FDA cleared device as a predicate, Cyrcadia Health™ (a division of Cyrcadia, Inc.) is combining the Company’s fourth generation, wearable device technology, made by Flextronics, and the SalesForce database software, to track the clinical results. Previous trials, conducted by Lifeline Biotechnologies, tested over 500 participants in developing, validating and patenting the technology. Utilizing the non-compressive, non-irradiative technology demonstrated significant promise in addressing the dense breast tissue population by using machine-learning predictive algorithms. With a higher propensity for cancer and limitations of current imaging standards, such as mammography, Cyrcadia Health’s screening technology could provide a much earlier alert to the state of cancer for this difficult to image population.

About Lifeline Biotechnologies, Inc. In 2008, Lifeline Biotechnologies founded Cyrcadia, Inc. The main purpose of founding Cyrcadia was to establish a better value of its technology and to obtain financing at more favorable rates. LLBO’s primary asset is its investment in Cyrcadia, Inc. and is its largest single shareholder. LLBO also has a three to five percent (3% to 5%) revenue royalty based on all Cyrcadia product sales. Lifeline conducted three rounds of proof of concept trials; the results were validated by the Aero Space Engineers at Nanyang Technological University, Singapore. Nanyang’s Aero Space Engineers are recognized world leaders in “Pattern Recognition,” which is the basis of Lifeline’s technology. Lifeline owns all of the issued software patents which have been licensed to Cyrcadia

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company’s product or market acceptance of the product and regulatory and shareholder approval for anticipated actions

Social Media Disclosure: Investors and others should note that we announce material information to our investors using this website, press releases, public conference calls and webcasts. We also use social media to communicate with our subscribers and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the U.S. social media channels listed below (this list may be updated from time to time).

lbti.com
Lifeline Biotech Twitter Account